Scynexis (SCYX) Capital Expenditures Growth (3y) (2016 - 2021)
Scynexis (SCYX) Capital Expenditures Growth (3y) (2016 - 2021) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | -4.39% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | -11.01% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -0.22% |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 34.19% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -8.00% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 4.68% |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | -7.72% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Scynexis | 62.02 Mn | -52.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -95.15% |
| Sep 30, 2021 | 51.94% |
| Jun 30, 2021 | -29.03% |
| Mar 31, 2021 | 161.10% |
| Dec 31, 2018 | 27.96% |
| Sep 30, 2018 | 49.63% |
| Jun 30, 2018 | 3.96% |
| Mar 31, 2018 | -61.18% |
| Mar 31, 2017 | -69.99% |
| Dec 31, 2016 | -63.36% |
| Sep 30, 2016 | -44.02% |
| Mar 31, 2016 | -62.52% |